GI
PCVX icon

GAMMA Investing’s Vaxcyte PCVX Stock Holding History

GAMMA Investing’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$101K Buy
1,769
+422
+31% +$24.6K ﹤0.01% 1878
2026
Q2 		$78.3K Buy
1,347
+66
+5% +$3.58K ﹤0.01% 1990
2026
Q1 		$74.4K Buy
1,281
+359
+39% +$19.5K ﹤0.01% 1877
2025
Q4 		$42.5K Buy
922
+205
+29% +$9.17K ﹤0.01% 2176
2025
Q3 		$25.8K Buy
717
+206
+40% +$6.83K ﹤0.01% 2393
2025
Q2 		$16.6K Buy
511
+252
+97% +$8.26K ﹤0.01% 2552
2025
Q1 		$9.78K Sell
259
-99
-28% -$7.92K ﹤0.01% 2753
2024
Q4 		$29.3K Buy
358
+73
+26% +$7.25K ﹤0.01% 2059
2024
Q3 		$32.6K Buy
285
+56
+24% +$5.05K ﹤0.01% 1796
2024
Q2 		$17.3K Buy
229
+140
+157% +$9.53K ﹤0.01% 1943
2024
Q1 		$6.08K Buy
89
+44
+98% +$3.05K ﹤0.01% 2312
2023
Q4 		$3.21K Buy
+45
New +$2.34K ﹤0.01% 2414

Other funds holding PCVX

VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
TC
Trust Company Manhattan, Kansas $1.15B AUM 7.83% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
PS
Planning Strategies Lancaster, Pennsylvania $169M AUM

GAMMA Investing's PCVX Position: Q3 2026 in Review

GAMMA Investing increased its Vaxcyte (PCVX) stake by 31% in Q3 2026, buying an estimated $24.6K and bringing the position to 1,769 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #1878.

GAMMA Investing first reported a position in PCVX in Q4 2023 and has held it in 12 quarters since. 8 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • GAMMA Investing held 1,769 shares of Vaxcyte worth $101K as of Q3 2026.
  • GAMMA Investing bought 422 Vaxcyte shares in Q3 2026, an estimated $24.6K.
  • Vaxcyte made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #1878 holding.
  • GAMMA Investing first reported a position in Vaxcyte in Q4 2023 and has held it in 12 quarters since.
  • 8 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.